Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade

Stock Track11-14

Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.

The downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.

According to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121303799?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121303799","market":"us","top_or_hot":-1,"title":"Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade","media":"Stock Track","content":"<p>Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.</p>\n\n<p>The downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.</p>\n\n<p>According to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Monopar Therapeutics Plummets 7.48% Following Raymond James Downgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-14 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.</p>\n\n<p>The downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.</p>\n\n<p>According to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNPR","symbol_name":"Monopar Therapeutics","start_time":0,"source_url":"","article_id":"1121303799","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121303799","pubTimestamp":1763130781,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNPR":"Monopar Therapeutics"},"translate_title":"个股追踪|Raymond James下调评级后Monopar Therapeutics暴跌7.48%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNPR":1},"content_text":"Monopar Therapeutics (MNPR) saw its stock price plummet 7.48% in pre-market trading on Friday, following a downgrade from Raymond James. The investment firm lowered its rating on Monopar from Strong Buy to Outperform and cut its price target from $142 to $123.\nThe downgrade appears to have overshadowed positive sentiment from other analysts. Oppenheimer reiterated its Buy rating with a $115 price target, while BTIG maintained its Buy rating with a $104 target. Despite these bullish views, investors seem to be focusing on Raymond James' more cautious stance.\nAccording to FactSet, Monopar Therapeutics still maintains an average rating of Buy among analysts, with a mean price target of $112. This suggests that while Raymond James has tempered its outlook, the overall sentiment remains positive. However, the market's sharp reaction indicates that investors are reassessing their expectations for the company in light of the downgrade.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121303799","isCrawlerRequest":true}